



CHIMERIC THERAPEUTICS

CHIMERIC

PIONEERS IN CELL THERAPY

Investor Update | MAY 2025



CONFIDENTIAL. NOT FOR DISTRIBUTION





DISCLAIMER

Certain statements contained in this presentation, including, without limitation, statements containing the words “believes,” “plans,” “expects,” “anticipates,” and words of similar import, constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Chimeric (collectively, “Chimeric” or the “Company”) to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favourable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect

future events or developments except as required by law.

This presentation may not contain all the details and information necessary for you to make a decision or evaluation. Neither this presentation nor any of its contents may be used for any other purpose without the prior written consent of the Company.



INVESTMENT HIGHLIGHTS

4

4 Phase 1 clinical trials
under 3 FDA INDs at 4 leading US centres



Multiple clinical updates
in the next 12mths



Experienced leadership team
in cell therapy clinical development



CHM-CDH17
the ONLY CDH17 CAR-T in clinical trials



First in class
CLTX-CAR for brain cancer



Robust and long life
patent portfolio

CORPORATE PROFILE

Exchange

ASX: CHM

Share Price

\$0.005

52 Week Range

\$0.004 - 0.047

Market Cap

Approx 10m

Shares on issue

~\$1.6B

IPO 2021





CHM: BROAD PORTFOLIO

3 Novel cell therapies; 4 Clinical Trials

CHM CDH17 CAR-T

Technology from:



PHASE 1/2 TRIAL OPEN

3 sites active

CHM CLTX CAR-T

Technology from:



Phase 1A completed: COH

PHASE 1B TRIAL OPEN

1 site active

CHM CORE-NK 'OFF THE SHELF' NK

Technology from:



PHASE 1B
TRIAL OPEN

MD Anderson

PHASE 1B
TRIAL OPEN

Case Western



CHIMERIC THERAPEUTICS

CHM CDH17

Clinical Trial Update

MAY, 2025



ASX:
CHM

CONFIDENTIAL. NOT FOR DISTRIBUTION





CHM CDH17 CAR-T OVERVIEW

The first CDH17 CAR-T cell therapy in clinical trials in the world



CHM CDH17
CAR-T

Technology from:



CHM CDH17 CAR-T targets an antigen on the surface/cell membrane of many cancer cells, called CDH17.

Our CAR-T is unique, being the first CAR-T cell therapy under development, attacking this target.

The current Phase 1/2 trial is the culmination of ten years R&D at the University of Pennsylvania (UPenn) from the lab of the world pioneer in CAR-T cell therapy, Prof Carl June.



CHM CDH17 CAR-T PHASE 1/2 RAPIDLY RECRUITING

PHASE 1/2 TRIAL OPEN
RAPIDLY RECRUITING



Phase 1/2 open at 4 sites: UPENN, Sarah Cannon, Emory and UChicago

Cancer Targets: Gastric, Neuroendocrine Tumours and Colorectal

15 patients to be recruited:

4 patients dosed to date

3 more patients manufactured pending dosing

5 patients on waiting list

Encouraging early efficacy signals in Patient 2 with Neuroendocrine Tumour



CLINICAL PRELIMINARY RESULTS

CHM CDH17 DOSE LEVEL 1

50m Cells	Tumour Type	Status
Patient 1	CRC	Lost to follow up
Patient 2	NET	Stable Disease until day 150 minor progression
Patient 3	CRC	Stable Disease day 90
Patient 4	CRC	Progressive Disease

CRC= Colorectal Cancer (Bowel Cancer)


NET= NeuroEndocrine Tumor (Intestinal NET)



WHAT'S NEXT?

Safety clearance to Dose Level 2

- ✓ Patient 5,6,7 manufactured
- ✓ Commence dose level 2 – single dose of 150m cells
- ✓ Monitor safety for 28days for patient 5 (FDA requirement)



EXAMPLE ONLY:

Patient 5

June 1 – Day 0 Dose lvl 2

June 28 – DLT period ends
28 day scan

*This is an **example** and not a defined timeline of results*





CHIMERIC THERAPEUTICS

CHM CORE-NK

Clinical Trial Update

MAY, 2025



ASX:
CHM

CONFIDENTIAL. NOT FOR DISTRIBUTION





CHM CORE-NK OVERVIEW

Phase 1b clinical trials being lead by partner institutions

CHM CORE-NK 'OFF THE SHELF' NK

Technology from:



PHASE 1B
TRIAL OPEN

MD Anderson

PHASE 1B
TRIAL OPEN

Case Western

OFF THE SHELF: AKA ALLOGENEIC

NK cell expansion platform: **Universal Donor**

Positive Phase 1A Clinical Trial in Colorectal Cancer (CRC) and Acute Myeloid Leukaemia (AML)

Two ongoing Phase 1B Clinical Trials in AML and CRC

AML: **Cohort 1 cleared, moved to dose expansion for Cohort 2; up to 20 patients frontline**


Our partners MD Anderson and Case Western are supporting the majority share of the cost of these two trials



AML PHASE 1B COMBINATION CLINICAL TRIAL OPEN

CHM CORE-NK + AZA + VEN in front-line Acute Myeloid Leukaemia

Clinical Trials.gov Identifier: NCT05834244



CORE NK CELLS



FDA REGISTERED
CHEMOTHERAPY



FDA REGISTERED
BLOOD CANCER DRUG

Funded by our partners MD Anderson Cancer Center

THE UNIVERSITY OF TEXAS
MDAnderson
~~Cancer Center~~



CHM CORE-NK FRONTLINE PHASE 1 STUDY RESULTS

Complete response in AML in two patient of first three dosed

2 / 3 patients

DIAGNOSIS: AML

Not eligible for Chemo or Stem Cell Transplant

SAFETY: No dose limiting toxicities, no cytokine release syndrome, no GvHD

CORE-NK
INFUSION

Patient Doses + SOC

COMPLETE
RESPONSE i

DAY 28

CRi = no signs of cancer in response to treatment
Blood count yet to recover (standard for AML patients)



CHIMERIC THERAPEUTICS

CHIMERIC

PIONEERS IN CELL THERAPY

investors@chimerictherapeutics.com



ASX:
CHM

CONFIDENTIAL. NOT FOR DISTRIBUTION

